Alendronate plus cholecalciferol for the treatment of osteoporosis

Women's Health

Volumn 2, Issue 1, 2006, Pages 23-27

  Heaney, Robert P ^a  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Absorption; Alendronate; Bisphosphonate; Bone resorption; Calcium; Cholecalciferol; Falls; Fractures; Osteoporosis; Vitamin D3

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; COLECALCIFEROL;

ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; BONE NECROSIS; BONE REMODELING; DIETARY INTAKE; DISEASE EXACERBATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ESOPHAGUS DISEASE; FALLING; FEMALE; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; JAW DISEASE; MALE; NUTRITIONAL REQUIREMENT; OSTEOLYSIS; OSTEOPOROSIS; RISK REDUCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VITAMIN SUPPLEMENTATION;

EID: 33646787856     PISSN: 17455057     EISSN: 17455065     Source Type: Journal    
DOI: 10.2217/17455057.2.1.23     Document Type: Article

References (33)

1. Riggs BL, Melton LJ III: The worldwide problem of osteoporosis: insights afforded by epidemiology. Bone 17(Suppl. 5), S505-S511 (1995).
2. Barrett JA, Baron JA, Beach ML: Mortality and pulmonary embolism after fracture in the elderly. Osteoporos. Int. 14, 889-894 (2003).
3. Johnell O, Kanis JA, Oden A et al.: Mortality after osteoporotic fractures. Osteoporos. Int. 15, 38-42 (2004).
4. Looker AC. Dawson-Hughes B, Calvo MS, Gunter EW, Sahyoun NR: Serum 25-hydroxyvitamin D status of adolescents and adults in two seasonal subpopulations from NHANES III. Bone 30, 771-777 (2002).
5. Holick MF, Siris ES, Binkley N et al: Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J. Clin Endocrinol. Metab. 90, 3215-3224 (2005).
6. Bischoff-Ferrari HA, Dietrich T, Orav EJ. Dawson-Hughes B: Positive association between 25-hydroxy vitamin D levels and bone mineral density: a population-based study of younger and older adults. Am. J. Med. 116, 634-639 (2004).
7. Parfitt AM: The evolution of vitamin D-related bone disease: the importance of an early stage of increased bone turnover without impaired mineralization. In: Nutritional Aspects of Osteoporosis. Burckhardt P. Dawson-Hughes B, Heaney RP (Eds). Academic Press, CA, USA, 197-208 (2001).
8. Bischoff-Ferrari HA, Dietrich T, Orav EJ et al.: Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged λ60 y. Am. J. Clin. Nutr. 80, 752-758 (2004).
9. Bischoff-Ferrari HA, Dawson-Hughes B. Willett WC et al: Effect of vitamin D on falls. J. Am. Med. Assoc. 291, 1999-2006 (2004).
10. Bischoff HA, Stäehelin HB, Dick W et al: Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J. Bone Miner. Res. 18. 343-351 (2003).
11. Recker RR, Gallagher R, MacCosbe PE: Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin. Proc. 80, 856-861 (2005).
12. Grant AM, Anderson FH, Avenell A et al.: Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium OR vitamin D, RECORD): a randomized placebo-controned trial. Lancet 365, 1621-1628 (2005).
13. Dietary Relerence Intakes for Calcium, Magnesium, Phosphorus, Vitamin D, and Fluoride. Food and Nutrition Board, Institute of Medicine. National Academy Press, DC, USA (1997).
14. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ: Human serum 25-hydroxy-cholecalciferol response to extended oral dosing with cholecalciferol. Am. J. Clin. Nutr. 77, 204-210 (2003).
15. Russell RG, Rogers MJ, Frith JC et al.: The pharmacology of bisphosphonates and new insights into their mechanisms of action. J. Bone Miner. Res. 14(Suppl. 2), 53-65 (1999).
16. Fisher JE, Rogers MJ, Halasy JM et al.: Alendronate mechanisms of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc. Natl Acad. Sci. 96, 133-138 (1999).
17. Delmas PD: The use of bisphosphonates in the treatment of osteoporosis. Curr. Opin. Rheumatol. 17, 462-466 (2005).
18. Recker RR, Lappe JM, Davies KM, Heaney RP: Bone remodeling increases substantially in the years after menopause and remains increased in older osteoporosis patients. J. Bone Miner. Res. 19, 1628-1633 (2004).
19. Recker RR, Davies KM, Barger-Lux MJ: Treatment of postmenopausal osteoporosis with oral ibandronate reduces activation frequency to healthy premenopausal values. J. Bone Miner. Res. 20(Suppl. 1) (2005) (In press).
20. Heaney RP, Yates AJ, Santora AC II: Bisphosphonate effects and the bone remodeling transient. J. Bone Miner. Res. 12, 1143-1151 (1997).
21. Greenspan SL, Holland S, Maitland-Ramsey I. et al.: Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy. Proc. Assoc. Am. Physicians 108, 230-238 (1996).
22. Holick MF: Vitamin D: Importance in the prevention of cancers, Type 1 diabetes, heart disease, and osteoporosis. Am. J. Clin. Nutr. 79, 362-371 (2004).
23. Cantorna MT, Mahon BD: Mounting evidence for vitamin D as an environmental factor affecting autoinunune disease prevalence. Exp. Biol. Med. 229, 1136-1142 (2004).
24. Gray RW, Weber HP, Dominguez JH, Lemann J: The metabolism of vitamin D3 and 25-hydroxyvitamin D3 in normal and anephric humans. J. Clin. Invest. Metab. 39, 1045-1056 (1974).
25. Papapoulos SE, Quandt SA, Liberman UA, Hochberg MC, Thompson D: Meta-analysis of the efficacy of alendronate for the prevention of hip fractures in postmenopausal women. Osteoporos. Int. 16, 468-474 (2005).
26. Cranney A, Wells G, Willan A et al: Meta-analyses of therapies for postmenopausal osteoporosis. II Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr. Rev. 23, 508-516 (2002).
27. Karpf DB, Shapiro DR, Seeman E et al.: Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups. J. Am. Med. Assoc. 277, 1159-1164 (1997).
28. Chapuy MC, Arlot ME, Duboeuf F et al.: Vitamin D3 and calcium to prevent hip fractures in elderly women. N. Engl. J. Med. 327, 1637-1642 (1992).
29. Dawson-Hughes, B, Harris SS, Krall EA, Dallal GE: Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N. Engl. J. Med. 337, 670-676 (1997).
30. Trivedi DP, Doll R, Khaw KT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and mortality in men and women living in the community: randomised double-blind controlled trial. Br. Med. J. 326, 469-474 (2003).
31. Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson-Hughes B: Fracture prevention with vitamin D supplementation. J. Am. Med. Assoc. 293, 2257-2264 (2005).
32. Lips PT, Recker RR, Rosen CJ et al.: The effect of a once-weekly tablet containing alendronate and vitamin D3 for the treatment of osteoporosis. J. Bone Miner. Res. 20(Suppl. 1) (2005) (In press).
33. Ruggiero SL, Mehrotra B, Rosenberg TJ. Engroff SL: Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg. 62, 527-534 (2004).